Biotech Company Valuation
Who this is for
Biotech founders preparing for Series B through IPO, corporate development teams evaluating licensing deals, and venture investors marking portfolio positions to market will find this the most relevant starting point.
What drives value in Biotech
- Pipeline stage and probability of regulatory success by asset
- Breadth and enforceability of patent portfolio
- Platform versus single-asset risk profile
- Existing partnerships, co-development agreements, or licensing revenue
- Management team's track record of prior exits or approvals
- Cash runway relative to next value-creating milestone
Valuation methods we use
Pre-revenue biotech companies are most commonly valued using risk-adjusted net present value (rNPV), which discounts probability-weighted peak sales estimates back to today. Comparable transaction analysis on similar-stage asset acquisitions provides a market-based cross-check. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.
Typical metrics and inputs
Pipeline stage
The most advanced clinical or regulatory stage of the lead asset (Preclinical through NDA/BLA).
Peak sales estimate
Analyst or management projection of peak annual revenue if the asset reaches commercialization.
Probability of success (PoS)
Historical regulatory approval rates by indication and stage; used to risk-weight cash flows.
Cash runway
Months of operating expenses covered by current cash; short runway creates valuation pressure.
Burn rate
Monthly cash consumption; high burn relative to milestones signals dilution risk.
Example scenarios
Phase 2 oncology asset
A biotech with a Phase 2 oncology candidate targeting a $2 B peak-sales indication and a 25% PoS might generate an rNPV of $80–120 M on that single asset alone.
Platform technology with two IND filings
A platform company with two IND-stage programs and a strong management team might trade at a $40–70 M pre-money valuation in a Series B, reflecting pipeline optionality.
Frequently asked questions
How do you value a pre-revenue biotech?
The most common method is risk-adjusted NPV (rNPV): estimate peak sales, apply probability of approval, and discount future cash flows to present value.
What discount rate is used for biotech DCF?
Biotech-specific discount rates typically range from 15–30%, reflecting development risk and binary outcomes.
How much does a Phase 2 asset add to valuation?
Phase 2 assets in large indications can add $50–300 M in rNPV depending on the indication size, competitive landscape, and probability of success.
Does platform technology get valued separately?
Yes — platforms with optionality across multiple indications command a premium over single-asset companies, typically reflected in higher exit multiples.
Is this a certified appraisal?
No. ValueAlpha provides AI-generated estimates for planning purposes. For formal transactions, engage a life sciences-focused financial advisor.
Run your Biotech valuation
Get a professional-grade valuation report using DCF, comparable companies, precedent transactions, and scenario analysis — for just $9.99.
Join the waitlist →Related industries
Biotech & Pharma
Value a biotech or pharmaceutical company using rNPV, pipeline analysis, and pharma comparable transactions. AI-powered reports for $9.99.
Healthcare Devices
Value a medical device company using revenue multiples, regulatory clearance premium, and pipeline analysis. Reports for $9.99.
Medical Labs
Value a clinical laboratory, pathology lab, or diagnostic testing company using EBITDA multiples and revenue per accession analysis. Reports for $9.99.
Healthcare Services
Value a healthcare services company using EBITDA multiples, revenue per provider, and payer mix analysis. AI-powered reports for $9.99.